Abivax's Offering Yields $920M Following Over-Allotment Exercise

Paris-based biotechnology firm Abivax SA has announced that it successfully exercised the full over-allotment option for its recent American Depositary Shares (ADSs) offering in the United States. The additional 960,000 ADSs raise the gross proceeds to approximately $920 million (€807 million). This represents a 15% increase over the initially offered 6,400,000 ADSs, culminating in a total of 7,360,000 ADSs issued. The offering is expected to close on July 6, 2026.

The funds raised will primarily support the potential commercialization of Abivax's lead drug candidate, obefazimod, in treating ulcerative colitis and Crohn’s disease. Additionally, proceeds will be allocated to further clinical research and development, with any remainder earmarked for general corporate needs.

The offering was priced at $125 per Additional ADS, a slight premium on the recent average market price, and was approved under resolutions from the May 11, 2026, shareholder meeting. Listed on Nasdaq under "ABVX," Abivax's shares also trade on Euronext Paris.